There are 105 resources available
Q&A and live discussion
Presenter: Andres Cervantes
Session: Presidential Symposium III
Resources:
Webcast
LBA6_PR - Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Presenter: Markus Moehler
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA7_PR - Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
Presenter: Narikazu Boku
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA8_PR - Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
Presenter: Ken Kato
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA9_PR - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
Presenter: Ronan Kelly
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast